Federal Minister of Justice and Attorney General of Canada Jody Wilson-Raybould today announced UBC's successful CFI Infrastructure Fund awardees. The largest grant, $9 million, was awarded to a research program led by Dr. Artem Cherkasov, titled Accelerated Drug Discovery Using Clinical Translation (ADDUCT).
Thee publications out of the VPC describing work towards the development of new therapeutics were published in the last week.
The results of research awards from two agencies today demonstrate the VPC's successful translation of basic research into discoveries that are moving to clinical applications.
July 26, 2017 - TORONTO, ON - Continuing their longstanding tradition of partnering to fund high quality Canadian prostate cancer research, Prostate Cancer Canada (PCC) and The Movember Foundation today announced two new projects with very real potential to make a tangible difference in the lives of men living with aggressive forms of prostate cancer.
The Best of the AACR Journals collection 2016 highlights the most-cited articles published in 2015 across the AACR journals.
The Journal of the National Cancer Institute today published a landmark multi-institutional study describing the first comprehensive comparison of blood-based tumour biopsy versus metastatic tissue biopsy for lethal prostate cancer.
Congratulations to Drs. Collins, Daugaard & Wang on being awarded five-year grants in the CIHR Project Grant: Fall 2016 competition. Dr. Wang is also a co-investigator on a five-year grant awarded to Dr. He at University Health Network (Toronto). Congratulations also to Dr. William Morris of the BC Cancer Agency and his research team, including our Centre's Dr. Alan So, on being awarded a six-year grant in the same competition.
UBC Media release: April 20, 2017
A drug created from a malaria protein stopped tumour growth of chemotherapy-resistant bladder cancer, offering hope for cancer patients not responding to standard treatments.
NEPC is a highly aggressive cancer that sometimes emerges in prostate cancer patients undergoing androgen deprivation therapy (ADT). Unfortunately ADT, which is common treatment for prostate cancer, had led to a correlating increase in cases of an aggressive variant called treatment-induced NEPC.
The VPC's My Precision Oncology Program (MyPOP) is the lead story in the Nov. 22, 2016 issue of Research Insider, the Vancouver Coastal Health Research Institute's newsletter. The article includes an interview with Dr. Kim Chi, Associate Director of Clinical Research at our Centre. Read the full article here (opens in new window).